Trial Profile
A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; MF 59
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 01 Mar 2012 Actual patient number of the extension trial is 637 as reported by ClinicalTrials.gov (NCT00912496).
- 01 Mar 2012 Actual patient number of the extension trial is 637 as reported by ClinicalTrials.gov (NCT00912496).
- 01 Mar 2012 Actual end date of the extension trial is Dec 2011 as reported by ClinicalTrials.gov (NCT00912496).